Results 181 to 190 of about 2,478,440 (395)
Large-scale analysis of disease pathways in the human interactome
, 2017 Discovering disease pathways, which can be defined as sets of proteins associated with a given disease, is an important problem that has the potential to provide clinically actionable insights for disease diagnosis, prognosis, and treatment ...
Agrawal, Monica +2 more
core +1 more source
The IFNγ‐CIITA‐MHC II axis modulates melanoma cell susceptibility to NK‐cell‐mediated cytotoxicity
Molecular Oncology, EarlyView.Natural killer (NK) cells play a central role in anti‐melanoma immunity. However, melanoma cells adapt during co‐culture by upregulating CIITA and MHC II in response to interferon gamma (IFNγ), thereby evading NK‐cell lysis. Blocking IFNγ signaling or treatment with dimethyl fumarate/simvastatin counteracts this immune escape and maintains NK‐cell ...
Lena C. M. Krause +6 more
wiley +1 more source
Modern methods of diagnosing benign and malignant lung neoplasms in children [PDF]
, 2019 O. V. Bilokon
openalex +1 more source
Molecular Oncology, EarlyView.Detection of extrachromosomal circular DNA (eccDNA) in plasma samples from EGFR‐mutated non‐small cell lung cancer patients. Plasma was collected before and during treatment with the EGFR‐tyrosine kinase inhibitor osimertinib. Plasma eccDNA was detected in all cancer samples, and the presence of the EGFR gene on eccDNA serves as a potential biomarker ...
Simone Stensgaard +5 more
wiley +1 more source
A 44-Year-Old Woman With Multiple Neoplasms and Cystic Lung Disease
, 2021 Natalia Moguillansky, Ali Ataya
openalex +1 more source
Molecular Oncology, EarlyView.A mouse model for vascular normalization and a human breast cancer cohort were studied to understand the relationship between vascular leakage and tumor immune suppression. For this, endothelial and immune cell RNAseq, staining for vascular function, and immune cell profiling were employed.
Liqun He +8 more
wiley +1 more source
Human medicines European public assessment report (EPAR): Zirabev, bevacizumab, Colorectal Neoplasms,Breast Neoplasms,Carcinoma, Non-Small-Cell Lung,Carcinoma, Renal Cell,Uterine Cervical Neoplasms, Date of authorisation: 14/02/2019, Revision: 1, Status: Authorised [PDF]
, 2019 openalex +1 more source
Molecular Oncology, EarlyView.RAS‐targeted therapies have become a clinical reality. Although promising results in patients have been achieved, there are still challenges ahead such as coping with drug resistance. Here we summarize selected RAS inhibitors targeting either individual KRAS mutant isoforms (KRASG12C, KRASG12D, KRASG12V) or exhibiting a wider inhibitory spectrum ...
Matthias Drosten, Mariano Barbacid
wiley +1 more source